The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin‐resistant subjects
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Introduction: Obese insulin‐resistant individuals exhibit a dyslipidaemia due to raised levels of both hepatically and intestinally derived lipoproteins. However, little is known about the related dysregulation of intestinally derived lipoproteins. We examined whether the insulin‐sensitizing agents, metformin and rosiglitazone, improve intestinal lipoprotein metabolism in obese insulin‐resistant individuals. Methods: Thirty male obese (body mass index > 26; waist circumference > 100 cm) insulin‐resistant [homeostasis model assessment (HOMA) score > 2.0] subjects were randomized to either a metformin (1 g bd), rosiglitazone (4 mg bd) or control treatment group for a period of 8 weeks. Fasting and postprandial lipid metabolism was studied before and after the intervention period. Results: Metformin and rosiglitazone both significantly improved insulin sensitivity, but this was not paralleled by improvement in dyslipidaemia. With rosiglitazone relative to control there was a significant (p < 0.05) increase in the area under the apolipoprotein (apo) B48 curve following the oral fat load and a decrease in the ratio of triglyceride to apo B48 levels postprandially following rosiglitazone treatment. Conclusion: In obese insulin‐resistant subjects metformin and rosiglitazone both improve insulin sensitivity, as measured by HOMA, without improvement in lipid metabolism. Rosiglitazone may have a detrimental effect on chylomicron metabolism by an increase in postprandial apo B48 levels, and this requires further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
Cohn, J. S., Johnson, E. J., Millar, J. S., Cohn, S. D., Milne, R. W., Marcel, Y. L., Russell, R. M., & Schaefer, E. J. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35345-1 · Cited by 248
Eberly, L. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1077 · Cited by 226
Identification of lipoproteins of intestinal origin in human atherosclerotic plaque
Pal, S., Semorine, K., Watts, G. F., & Mamo, J. (2003) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2003.120 · Cited by 107
Self-citationJames, A. P., Watts, G. F., Barrett, P. H. R., Smith, D., Pal, S., Chan, D. C., & Mamo, J. C. L. (2003) · Metabolism · doi:10.1053/meta.2003.50032 · Cited by 54
Self-citation
Cited by
Changes in Plasma Free Fatty Acids Associated with Type-2 Diabetes
I. S. Sobczak, A., A. Blindauer, C., & J. Stewart, A. (2019) · Nutrients · doi:10.3390/nu11092022 · Cited by 304
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus
Salpeter, S. R., Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.09.016 · Cited by 248
New insights into the regulation of chylomicron production
Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034338 · Cited by 194
Lim, S. S., Noakes, M., Keogh, J. B., & Clifton, P. M. (2010) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.05.003 · Cited by 68
Eleftheriadou, I., Grigoropoulou, P., Katsilambros, N., & Tentolouris, N. (2008) · Current Diabetes Reviews · doi:10.2174/157339908786241133 · Cited by 55
Metadata
- Authors
- James, A. P., Watts, G. F., & Mamo, J. C. L.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2004-11-24
- Volume
- 7
- Issue
- 4
- Pages
- 381-389
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2021842632
- Cited by
- 40
- References
- 10
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin‐resistant subjects. https://app.cochat.ai/papers/10.1111/j.1463-1326.2004.00407.x
- The paper
- James, A. P., Watts, G. F., & Mamo, J. C. L. (2005). The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin‐resistant subjects. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2004.00407.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.